Indica and Magnisnese work on magnetic marker diagnostics

Magnisense, a developer of immunoassays for human and animal diagnostics, is offering a new platform developed with The French company Indicia Biotechnology, which enables diagnostics companies to test solutions based on its novel magnetic bead technology, MIAtek.

MIAtek employs magnetic beads as markers, replacing the traditional enzymatic or fluorescent methods. Magnisense has already developed a portable reader that can identify and quantify accurately a biological target using superparamagnetic beads as markers.

By linking up with Indicia, Magnisense opens the way for diagnostics or life science companies who wish to use MIAtek for their own applications to develop quickly and economically tests which are specifically adapted to the desired markers and based on their own parameters.

Indicia Biotechnology offers custom designed services focusing on development and manufacturing of immunoassays and reagents.

"Any of our customers can now rapidly judge the value of our technology thanks to our jointly-developed tests", said Luc Lenglet, ceo of Magnisense. "Indicia brings two indispensable skills to the development of MIAtek technology: immunoassays and reagents for the magnetic beads."

Stephane Legastelois, chairman of Indicia Biotechnology, said: "Companies interested in Magnisense's technology can now see quickly and easily for themselves the advantages such as the increased sensitivity and the quantification of fast testing."